Skip to content

RB1 genetics and heritability

TL;DR — Retinoblastoma usually requires functional loss of both RB1 alleles, but heritable and non-heritable disease differ in where the first hit occurs. A constitutional pathogenic variant makes every retinal cell—and other tissues—carry the first hit; a purely somatic pair confines predisposition to the tumour lineage. Bilateral or multifocal disease strongly indicates heritable disease, but unilateral presentation does not exclude constitutional or mosaic RB1. The distinction changes eye surveillance, sibling and offspring risk, reproductive counselling and lifelong subsequent-neoplasm risk.

Decision-relevant evidence

  • Knudson inferred two mutational events from 48 cases; the second event produces an average of about three retinoblastomas per carrier, which is what makes occasional non-penetrance, unilateral presentation in carriers and multifocal tumours in one eye all compatible with the same model (Knudson 1971, PMID 5279523).

  • Both alleles are usually inactivated; rare tumours instead show high-level MYCN amplification with wild-type RB1 (Li 2016, PMID 27155049). One overview places the MYCN-driven fraction at about 2% of cases and heritable disease at 30–40%, with roughly 60% of presentations unilateral and 40% bilateral, and notes that about 15% of unilateral cases carry a germline or mosaic RB1 defect (Abu-Amero 2025, PMID 41009976).

  • Predisposition is transmitted as an autosomal dominant trait, and expressivity is not fixed: the mean number of tumour foci in carriers varies with how much normal allele function is retained and is further modified by background genetic factors, which is why "carrier" alone is a weak predictor of an individual child's course (Lohmann 2010, PMID 20687510).

  • In a molecular series of isolated unilateral disease, a constitutional mutation was detected in 6 of 36 mutation-informative patients (17%); one of those patients had demonstrable somatic mosaicism, and mosaicism was suspected in two further patients without a detectable blood mutation, one with multifocal tumours and one who later developed bilateral disease (Lohmann 1997, PMID 9311732).

  • Modern paired-sample sequencing shows how large that mosaic fraction actually is: among 136 consecutive patients tested with paired plasma cell-free DNA and buffy-coat DNA, RB1 mosaicism was found in 20 (14.7%), and four of those had previously tested germline-negative at outside laboratories. Mosaic patients were less likely than heterozygous patients to have bilateral disease (55.0% versus 91.7%; difference 36.7%, 95% CI 13.8–59.6; P = .002) (Gao 2025, PMID 40338593).

  • Parental mosaicism is the quantity that actually governs sibling risk, and it is small but not negligible. Deep sequencing of both unaffected parents of 124 consecutive bilateral probands found one mosaic parent, giving a maximal recurrence risk of 0.4%; observed recurrences in the sibships gave 0.8%. Both estimates are 266- to 533-fold above the general-population risk (Dehainault 2017, PMID 28000698).

  • Detection rate depends sharply on laterality. In 50 Indian children, germline testing by next-generation sequencing plus MLPA gave a mutation detection rate of 86.2% in bilateral and 19% in unilateral disease; the mutation-positive group had more recurrence (P = 0.021), more progression (P < 0.001) and more optic-nerve invasion, subretinal seeds and high-risk pathological features (Gupta 2021, PMID 34294096).

  • Timing of the first hit shows in the clinic: 7–10% of all retinoblastomas and 44–71% of familial retinoblastomas in high-income countries are diagnosed neonatally, and neonatal disease is usually germline even when the family history is negative. At least half of these infants are unilateral at diagnosis, but most germline carriers progress to bilateral involvement, typically group A in the fellow eye (Kivelä 2017, PMID 28695165).

  • Germline status is the input to the "H" category of AJCC staging and to the surveillance plan, not merely a research variable: it determines the risk of further tumours in the same and the fellow eye and the lifetime risk of non-ocular malignancy, and so decides who needs intensive ocular and brain surveillance and who needs none (Mallipatna 2016, PMID 27488068; Abu-Amero 2025, PMID 41009976).

  • The heritability split is quantitatively decisive downstream: overall subsequent-malignancy SIR was 11.9 (95% CI 10.4–13.5) in 1,128 heritable survivors versus 0.8 (0.5–1.2) in 924 non-heritable survivors, with 50-year cumulative incidence 33.1% (29.0–37.2) for a first subsequent neoplasm in the heritable group (Schonfeld 2021, PMID 33473166).

  • RB1 loss has consequences outside the retina that are being mapped mechanistically. An induced-pluripotent-stem-cell model of hereditary retinoblastoma found that pRB and E2F3a co-regulate more than one third of spliceosomal genes, that spliceosome inhibition in RB1-mutant cells causes global intron retention and impaired tumorigenesis, and that high pRB/E2F3a-regulated spliceosomal gene expression tracks worse osteosarcoma survival — a candidate route from germline RB1 status to second-cancer biology (Tu 2022, PMID 35412907).

Clinical and research frame

Domain Operational meaning Evidence boundary
Constitutional first hit Blood or mosaic tissues Bilateral/multifocal common; relatives may be at risk
Post-zygotic mosaic first hit Fraction of tissues Phenotype and transmission depend on timing/distribution
Two somatic hits Tumour only Usually unilateral; offspring risk falls if confidently resolved
MYCN-amplified, RB1-wild-type Tumour Rare aggressive biological subgroup

Interpretation rules

  • Keep the child-level endpoints of survival and metastasis separate from the eye-level endpoint of globe salvage.

  • Report initial stage, laterality, heritability, prior treatment and follow-up; otherwise comparisons are not transportable.

  • A retrospective eye series estimates performance in selected eyes; it does not establish superiority over another route.

  • Absence of metastasis in a small series is a safety observation, not proof that risk is zero.

  • Treatment-era effects matter because external-beam radiotherapy, systemic chemotherapy, IAC and intravitreal therapy create different late-risk profiles.

  • Income stratum and access are effect modifiers, not background descriptors (Global Retinoblastoma Study Group 2022, PMID 35839812).

Evidence register

The following records were each retrieved live from PubMed E-utilities on 2026-09-01 and re-fetched live during the independent audit on the same date. Every identifier below resolved, and its author, year, journal and title matched the citation as written. Inclusion records the evidence base for this page; a register entry asserts that the record exists and is on topic, not that it supports a specific effect estimate.

PMID Year Study or review Role in this page
5279523 1971 Mutation and cancer: statistical study of retinoblastoma. Topic-resolved source (Knudson 1971, PMID 5279523)
27155049 2016 A Rapid and Sensitive Next-Generation Sequencing Method to Detect RB1 Mutations Improves Care for Retinoblastoma Patients and Their Families. Topic-resolved source (Li 2016, PMID 27155049)
9311732 1997 Constitutional RB1-gene mutations in patients with isolated unilateral retinoblastoma. Topic-resolved source (Lohmann 1997, PMID 9311732)
33473166 2021 Long-term risk of subsequent cancer incidence among hereditary and nonhereditary retinoblastoma survivors. Topic-resolved source (Schonfeld 2021, PMID 33473166)
35839812 2022 The Global Retinoblastoma Outcome Study: a prospective, cluster-based analysis of 4064 patients from 149 countries. Topic-resolved source (Global 2022, PMID 35839812)
27189421 2015 Retinoblastoma. Topic-resolved source (Dimaras 2015, PMID 27189421)
38615905 2024 Recent progress in retinoblastoma: Pathogenesis, presentation, diagnosis and management. Topic-resolved source (Zhou 2024, PMID 38615905)
25435120 2015 Retinoblastoma. Topic-resolved source (Rodriguez-Galindo 2015, PMID 25435120)
28695165 2017 Neonatal Retinoblastoma. Topic-resolved source (Kivelä 2017, PMID 28695165)
16934146 2006 Retinoblastoma. Topic-resolved source (Aerts 2006, PMID 16934146)
20687510 2010 Retinoblastoma. Topic-resolved source (Lohmann 2010, PMID 20687510)
27488068 2016 Genetics of Retinoblastoma. Topic-resolved source (Mallipatna 2016, PMID 27488068)
35412907 2022 Hereditary retinoblastoma iPSC model reveals aberrant spliceosome function driving bone malignancies. Topic-resolved source (Tu 2022, PMID 35412907)
36408154 2022 Retinoblastoma: Review and new insights. Topic-resolved source (Cruz-Gálvez 2022, PMID 36408154)
28674118 2017 Retinoblastoma and Neuroblastoma Predisposition and Surveillance. Topic-resolved source (Kamihara 2017, PMID 28674118)
26679524 2016 [Retinoblastoma update]. Topic-resolved source (Aerts 2016, PMID 26679524)
40993897 2025 Retinoblastoma: Advances in Genetic Testing. Topic-resolved source (Lindquist 2025, PMID 40993897)
24793631 2014 [Retinoblastoma: recent advances]. Topic-resolved source (Jehanne 2014, PMID 24793631)
40338597 2025 DNA Assays to Detect and Characterize RB1 Mosaicism in Retinoblastoma. Topic-resolved source (Chévez-Barrios 2025, PMID 40338597)
40338593 2025 Detection and Characterization of RB1 Mosaicism in Patients With Retinoblastoma Receiving cfDNA Test. Topic-resolved source (Gao 2025, PMID 40338593)
40619694 2025 Challenges for Early Diagnosis in Retinoblastoma in Low- and Middle-Income Countries. Topic-resolved source (Chantada 2025, PMID 40619694)
28000698 2017 Mosaicism and prenatal diagnosis options: insights from retinoblastoma. Topic-resolved source (Dehainault 2017, PMID 28000698)
34294096 2021 Retinoblastoma genetics screening and clinical management. Topic-resolved source (Gupta 2021, PMID 34294096)
38804799 2024 Retinoblastoma - A comprehensive review, update and recent advances. Topic-resolved source (Nag 2024, PMID 38804799)
37667345 2023 Retinoblastoma: present scenario and future challenges. Topic-resolved source (Byroju 2023, PMID 37667345)
35969246 2022 [Imaging of retinoblastoma : Current state-of-the-art and future prospects]. Topic-resolved source (Schweiger 2022, PMID 35969246)
22414599 2012 Retinoblastoma. Topic-resolved source (Dimaras 2012, PMID 22414599)
16570739 2006 Retinoblastoma. Topic-resolved source (Melamud 2006, PMID 16570739)
33583507 2021 Neonatal Retinoblastoma. Topic-resolved source (Lin 2021, PMID 33583507)
40731848 2025 Update on Retinoblastoma Therapies. Topic-resolved source (Martínez 2025, PMID 40731848)
34210807 2021 Update on the Treatment of Retinoblastoma. Topic-resolved source (Manrique 2021, PMID 34210807)
29321667 2018 The management of retinoblastoma. Topic-resolved source (Fabian 2018, PMID 29321667)
26969537 2016 Retinoblastoma: An update. Topic-resolved source (Delhiwala 2016, PMID 26969537)
10761080 1998 Retinoblastoma. Topic-resolved source (Margo 1998, PMID 10761080)
38492167 2024 Epidemiology, Diagnosis and Genetics of Retinoblastoma: ICMR Consensus Guidelines. Topic-resolved source (Singh 2024, PMID 38492167)
40235228 2025 Genetics of Retinoblastoma - An Update. Topic-resolved source (Nag 2025, PMID 40235228)
36470558 2023 Retinoblastoma: From genes to patient care. Topic-resolved source (Bouchoucha 2023, PMID 36470558)
3323180 1987 Intraocular and extraocular retinoblastoma. Topic-resolved source (Grabowski 1987, PMID 3323180)
37658463 2023 Genetics in ophthalmology: molecular blueprints of retinoblastoma. Topic-resolved source (Marković 2023, PMID 37658463)
41009976 2025 Genetics of Retinoblastoma: An Overview and Significance of Genetic Testing in Clinical Practice. Topic-resolved source (Abu-Amero 2025, PMID 41009976)

Source chronology

Era marker PMID What the record contributes
1971 5279523 Mutation and cancer: statistical study of retinoblastoma. (Knudson 1971, PMID 5279523)
1987 3323180 Intraocular and extraocular retinoblastoma. (Grabowski 1987, PMID 3323180)
1997 9311732 Constitutional RB1-gene mutations in patients with isolated unilateral retinoblastoma. (Lohmann 1997, PMID 9311732)
1998 10761080 Retinoblastoma. (Margo 1998, PMID 10761080)
2006 16570739 Retinoblastoma. (Melamud 2006, PMID 16570739)
2006 16934146 Retinoblastoma. (Aerts 2006, PMID 16934146)
2010 20687510 Retinoblastoma. (Lohmann 2010, PMID 20687510)
2012 22414599 Retinoblastoma. (Dimaras 2012, PMID 22414599)
2014 24793631 [Retinoblastoma: recent advances]. (Jehanne 2014, PMID 24793631)
2015 25435120 Retinoblastoma. (Rodriguez-Galindo 2015, PMID 25435120)
2015 27189421 Retinoblastoma. (Dimaras 2015, PMID 27189421)
2016 26679524 [Retinoblastoma update]. (Aerts 2016, PMID 26679524)
2016 26969537 Retinoblastoma: An update. (Delhiwala 2016, PMID 26969537)
2016 27155049 A Rapid and Sensitive Next-Generation Sequencing Method to Detect RB1 Mutations Improves Care for Retinoblastoma Patients and Their Families. (Li 2016, PMID 27155049)
2016 27488068 Genetics of Retinoblastoma. (Mallipatna 2016, PMID 27488068)

Evidence limitations

  • Most intraocular treatment evidence is observational, single-centre and reported per eye; bilateral eyes within one child are statistically correlated.

  • Classification and treatment changed over time, producing stage migration and confounding by indication.

  • Rare metastatic and late-effect outcomes require multinational cohorts and decades of follow-up.

  • Verification is abstract-level. Every claim on this page was checked against the abstract of the record it cites during the independent audit on 2026-09-01; where an abstract could not support a claim, the claim was removed or restated as an explicit limit. Claims requiring full text beyond the abstract are not made here.

Open questions

  • What assay depth is needed to exclude clinically meaningful low-level mosaicism? The current evidence register defines the design space but does not close the question.

  • Which variant classes predict reduced penetrance well enough to alter surveillance? The current evidence register defines the design space but does not close the question.

  • How should heritability be assigned when tumour tissue is unavailable? The current evidence register defines the design space but does not close the question.

References

  1. Knudson AG. Mutation and cancer: statistical study of retinoblastoma. Proceedings of the National Academy of Sciences of the United States of America. 1971;68:820-3. PMID 5279523
  2. Li WL, et al. A Rapid and Sensitive Next-Generation Sequencing Method to Detect RB1 Mutations Improves Care for Retinoblastoma Patients and Their Families. The Journal of molecular diagnostics : JMD. 2016;18:480-93. PMID 27155049
  3. Lohmann DR, et al. Constitutional RB1-gene mutations in patients with isolated unilateral retinoblastoma. American journal of human genetics. 1997;61:282-94. PMID 9311732
  4. Schonfeld SJ, et al. Long-term risk of subsequent cancer incidence among hereditary and nonhereditary retinoblastoma survivors. British journal of cancer. 2021;124:1312-1319. PMID 33473166
  5. Global Retinoblastoma Study Group. The Global Retinoblastoma Outcome Study: a prospective, cluster-based analysis of 4064 patients from 149 countries. The Lancet. Global health. 2022;10:e1128-e1140. PMID 35839812
  6. Dimaras H, et al. Retinoblastoma. Nature reviews. Disease primers. 2015;1:15021. PMID 27189421
  7. Zhou M, et al. Recent progress in retinoblastoma: Pathogenesis, presentation, diagnosis and management. Asia-Pacific journal of ophthalmology (Philadelphia, Pa.). 2024;13:100058. PMID 38615905
  8. Rodriguez-Galindo C, et al. Retinoblastoma. Pediatric clinics of North America. 2015;62:201-23. PMID 25435120
  9. Kivelä TT, et al. Neonatal Retinoblastoma. Asia-Pacific journal of oncology nursing. 2017;4:197-204. PMID 28695165
  10. Aerts I, et al. Retinoblastoma. Orphanet journal of rare diseases. 2006;1:31. PMID 16934146
  11. Lohmann D. Retinoblastoma. Advances in experimental medicine and biology. 2010;685:220-7. PMID 20687510
  12. Mallipatna A, et al. Genetics of Retinoblastoma. Asia-Pacific journal of ophthalmology (Philadelphia, Pa.). 2016;5:260-4. PMID 27488068
  13. Tu J, et al. Hereditary retinoblastoma iPSC model reveals aberrant spliceosome function driving bone malignancies. Proceedings of the National Academy of Sciences of the United States of America. 2022;119:e2117857119. PMID 35412907
  14. Cruz-Gálvez CC, et al. Retinoblastoma: Review and new insights. Frontiers in oncology. 2022;12:963780. PMID 36408154
  15. Kamihara J, et al. Retinoblastoma and Neuroblastoma Predisposition and Surveillance. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017;23:e98-e106. PMID 28674118
  16. Aerts I, et al. [Retinoblastoma update]. Archives de pediatrie : organe officiel de la Societe francaise de pediatrie. 2016;23:112-6. PMID 26679524
  17. Lindquist M, et al. Retinoblastoma: Advances in Genetic Testing. International ophthalmology clinics. 2025;65:42-46. PMID 40993897
  18. Jehanne M, et al. [Retinoblastoma: recent advances]. Bulletin du cancer. 2014;101:380-7. PMID 24793631
  19. Chévez-Barrios P, et al. DNA Assays to Detect and Characterize RB1 Mosaicism in Retinoblastoma. JAMA ophthalmology. 2025;143:568-569. PMID 40338597
  20. Gao C, et al. Detection and Characterization of RB1 Mosaicism in Patients With Retinoblastoma Receiving cfDNA Test. JAMA ophthalmology. 2025;143:562-568. PMID 40338593
  21. Chantada GL, et al. Challenges for Early Diagnosis in Retinoblastoma in Low- and Middle-Income Countries. Pediatric blood & cancer. 2025;72:e31859. PMID 40619694
  22. Dehainault C, et al. Mosaicism and prenatal diagnosis options: insights from retinoblastoma. European journal of human genetics : EJHG. 2017;25:381-383. PMID 28000698
  23. Gupta H, et al. Retinoblastoma genetics screening and clinical management. BMC medical genomics. 2021;14:188. PMID 34294096
  24. Nag A, et al. Retinoblastoma - A comprehensive review, update and recent advances. Indian journal of ophthalmology. 2024;72:778-788. PMID 38804799
  25. Byroju VV, et al. Retinoblastoma: present scenario and future challenges. Cell communication and signaling : CCS. 2023;21:226. PMID 37667345
  26. Schweiger B, et al. [Imaging of retinoblastoma : Current state-of-the-art and future prospects]. Radiologie (Heidelberg, Germany). 2022;62:1067-1074. PMID 35969246
  27. Dimaras H, et al. Retinoblastoma. Lancet (London, England). 2012;379:1436-46. PMID 22414599
  28. Melamud A, et al. Retinoblastoma. American family physician. 2006;73:1039-44. PMID 16570739
  29. Lin FY, et al. Neonatal Retinoblastoma. Clinics in perinatology. 2021;48:53-70. PMID 33583507
  30. Martínez Arce CA, et al. Update on Retinoblastoma Therapies. Medicina (Kaunas, Lithuania). 2025;61. PMID 40731848
  31. Manrique M, et al. Update on the Treatment of Retinoblastoma. NeoReviews. 2021;22:e423-e437. PMID 34210807
  32. Fabian ID, et al. The management of retinoblastoma. Oncogene. 2018;37:1551-1560. PMID 29321667
  33. Delhiwala KS, et al. Retinoblastoma: An update. Seminars in diagnostic pathology. 2016;33:133-40. PMID 26969537
  34. Margo CE, et al. Retinoblastoma. Cancer control : journal of the Moffitt Cancer Center. 1998;5:310-316. PMID 10761080
  35. Singh L, et al. Epidemiology, Diagnosis and Genetics of Retinoblastoma: ICMR Consensus Guidelines. Indian journal of pediatrics. 2024;91:1147-1156. PMID 38492167
  36. Nag A, et al. Genetics of Retinoblastoma - An Update. Seminars in ophthalmology. 2025;40:609-617. PMID 40235228
  37. Bouchoucha Y, et al. Retinoblastoma: From genes to patient care. European journal of medical genetics. 2023;66:104674. PMID 36470558
  38. Grabowski EF, et al. Intraocular and extraocular retinoblastoma. Hematology/oncology clinics of North America. 1987;1:721-35. PMID 3323180
  39. Marković L, et al. Genetics in ophthalmology: molecular blueprints of retinoblastoma. Human genomics. 2023;17:82. PMID 37658463
  40. Abu-Amero KK, et al. Genetics of Retinoblastoma: An Overview and Significance of Genetic Testing in Clinical Practice. Genes. 2025;16. PMID 41009976